Skip to main content
. 2020 Jun 8;2020:6947382. doi: 10.1155/2020/6947382

Table 1.

Baseline patient and disease characteristics.

Characteristic Whole cohort (n = 153) CRP/Alb <0.75 (n = 92) CRP/Alb ≥0.75 (n = 61) P value
Median age, y (range) 59 (24–80) 60 (34–80) 57 (24–79) 0.73
Age group, n (%)
 <50 years 47 (30.7) 30 (32.6) 17 (27.9) 0.24
 ≥50 years 106 (69.3) 62 (67.4) 44 (72.1)
Gender, n (%)
 Female 53 (34.6) 32 (34.8) 21 (34.4) 0.83
 Male 100 (65.4) 60 (65.2) 40 (65.6)
KPS, n (%)
 90–100 93 (60.8) 56 (60.9) 37 (60.6) 0.92
 70–80 60 (39.2) 36 (39.1) 24 (39.4)
RTOG RPA class, n (%)
 III 60 (39.2) 41 (44.6) 19 (31.1) 0.19
 IV 63 (41.2) 39 (41.3) 24 (39.3)
 V 30 (19.6) 12 (18.5) 18 (29.6)
Symptom duration
 Median, mo (range) 1.9 (0.3–5.9 2.0 (0.3–5.9) 1.7 (0.3–4.4) 0.62
 <3 months, n (%) 113 (73.9) 69 (75.0) 44 (72.1)
 ≥3 months, n (%) 40 (26.1) 23 (25.0) 17 (27.9)
Tumor location, n (%)
 Frontal 37 (24.2) 22 (23.9) 15 (24.6) 0.71
 Parietal 29 (19.0) 18 (19.6) 11 (18.0)
 Temporal 34 (22.2) 20 (21.7) 14 (23.0)
 Occipital 15 (9.8) 9 (9.8) 6 (9.8)
 Midline 16 (10.5) 10 (10.9) 6 (9.8)
 Multilobar 22 (14.3) 13 (14.1) 9 (14.8)
Extent of surgery, n (%)
 Gross total 54 (35.3) 32 (34.8) 22 (36.1) 0.56
 Subtotal 74 (48.4) 44 (47.8) 30 (49.2)
 Biopsy 25 (16.3) 16 (17.4) 9 (14.7)
Corticosteroid use, n (%)
 Yes 104 (68.0) 62 (68.8) 42 (67.4) 0.80
 No 49 (32.0) 30 (31.2) 19 (32.6)
Anticonvulsant use, n (%)
 Yes 50 (32.7) 29 (31.5) 21 (34.4) 0.48
 No 103 (67.3) 63 (68.5) 40 (65.6)
Comorbid conditions, n (%)
 DM 10 (6.5) 6 (6.5) 4 (6.6) 0.91
 HT 7 (4.6) 4 (4.3) 3 (4.9) 0.42
 CAHD 5 (3.3) 3 (3.3) 2 (3.3) 0.98
 COPD 4 (2.6) 2 (2.2) 2 (3.3) 0.39
 CLD 2 (1.3) 1 (1.1) 1 (1.7) 0.48

CRP/Alb, CRP to albumin ratio; KPS, Karnofsky performance score; RTOG RPA, radiation therapy oncology group recursive partitioning analysis; DM, diabetes mellitus; HT, hypertension; CAHD, coronary artery heart disease; COPD, chronic obstructive lung disease; CLD, chronic liver disease.